> top > docs > PMC:7205724 > spans > 1466-1620 > annotations

PMC:7205724 / 1466-1620 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
51 44-47 Gene denotes IL6 Gene:3569
52 101-104 Gene denotes IL6 Gene:3569
61 82-90 Species denotes patients Tax:9606
62 145-154 Species denotes SARS-CoV2 Tax:2697049
64 1-12 Chemical denotes Tocilizumab MESH:C502936

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T5 27-35 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T18 145-149 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T5 14-15 http://purl.obolibrary.org/obo/CLO_0001020 denotes a

LitCovid-sample-PD-NCBITaxon

Id Subject Object Predicate Lexical cue ncbi_taxonomy_id
T18 145-154 Species denotes SARS-CoV2 NCBItxid:2697049

LitCovid-sample-sentences

Id Subject Object Predicate Lexical cue
T19 1-112 Sentence denotes Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels.

LitCovid-sample-Pubtator

Id Subject Object Predicate Lexical cue pubann:denotes
64 1-12 Chemical denotes Tocilizumab MESH:C502936
51 44-47 Gene denotes IL6 Gene:3569
61 82-90 Species denotes patients Tax:9606
52 101-104 Gene denotes IL6 Gene:3569
62 145-154 Species denotes SARS-CoV2 Tax:2697049

LitCovid-sample-UniProt

Id Subject Object Predicate Lexical cue uniprot_id
T177 44-47 Protein denotes IL6 https://www.uniprot.org/uniprot/Q9XT80|https://www.uniprot.org/uniprot/Q9UCU4|https://www.uniprot.org/uniprot/Q9UCU3|https://www.uniprot.org/uniprot/Q9UCU2|https://www.uniprot.org/uniprot/Q9MZR1|https://www.uniprot.org/uniprot/Q9MYZ7|https://www.uniprot.org/uniprot/Q95KN6|https://www.uniprot.org/uniprot/Q95181|https://www.uniprot.org/uniprot/Q90YI0|https://www.uniprot.org/uniprot/Q8MKH0|https://www.uniprot.org/uniprot/Q8BN26|https://www.uniprot.org/uniprot/Q865X6|https://www.uniprot.org/uniprot/Q865W7|https://www.uniprot.org/uniprot/Q6V919|https://www.uniprot.org/uniprot/Q6L6X6|https://www.uniprot.org/uniprot/Q5I6E3|https://www.uniprot.org/uniprot/Q3UCQ0|https://www.uniprot.org/uniprot/Q2MH06|https://www.uniprot.org/uniprot/Q28819|https://www.uniprot.org/uniprot/Q28747|https://www.uniprot.org/uniprot/Q28319|https://www.uniprot.org/uniprot/Q25BC2|https://www.uniprot.org/uniprot/Q0PW36|https://www.uniprot.org/uniprot/Q0GGL7|https://www.uniprot.org/uniprot/Q08DT2|https://www.uniprot.org/uniprot/P79341|https://www.uniprot.org/uniprot/P51494|https://www.uniprot.org/uniprot/P46650|https://www.uniprot.org/uniprot/P41693|https://www.uniprot.org/uniprot/P41683|https://www.uniprot.org/uniprot/P41323|https://www.uniprot.org/uniprot/P29455|https://www.uniprot.org/uniprot/P26893|https://www.uniprot.org/uniprot/P26892|https://www.uniprot.org/uniprot/P20607|https://www.uniprot.org/uniprot/P08505|https://www.uniprot.org/uniprot/P05231|https://www.uniprot.org/uniprot/O46568|https://www.uniprot.org/uniprot/O35736|https://www.uniprot.org/uniprot/O19007|https://www.uniprot.org/uniprot/B6CKP4|https://www.uniprot.org/uniprot/A9QWQ9|https://www.uniprot.org/uniprot/A3FBE9|https://www.uniprot.org/uniprot/A0S0B0
T221 101-104 Protein denotes IL6 https://www.uniprot.org/uniprot/Q9XT80|https://www.uniprot.org/uniprot/Q9UCU4|https://www.uniprot.org/uniprot/Q9UCU3|https://www.uniprot.org/uniprot/Q9UCU2|https://www.uniprot.org/uniprot/Q9MZR1|https://www.uniprot.org/uniprot/Q9MYZ7|https://www.uniprot.org/uniprot/Q95KN6|https://www.uniprot.org/uniprot/Q95181|https://www.uniprot.org/uniprot/Q90YI0|https://www.uniprot.org/uniprot/Q8MKH0|https://www.uniprot.org/uniprot/Q8BN26|https://www.uniprot.org/uniprot/Q865X6|https://www.uniprot.org/uniprot/Q865W7|https://www.uniprot.org/uniprot/Q6V919|https://www.uniprot.org/uniprot/Q6L6X6|https://www.uniprot.org/uniprot/Q5I6E3|https://www.uniprot.org/uniprot/Q3UCQ0|https://www.uniprot.org/uniprot/Q2MH06|https://www.uniprot.org/uniprot/Q28819|https://www.uniprot.org/uniprot/Q28747|https://www.uniprot.org/uniprot/Q28319|https://www.uniprot.org/uniprot/Q25BC2|https://www.uniprot.org/uniprot/Q0PW36|https://www.uniprot.org/uniprot/Q0GGL7|https://www.uniprot.org/uniprot/Q08DT2|https://www.uniprot.org/uniprot/P79341|https://www.uniprot.org/uniprot/P51494|https://www.uniprot.org/uniprot/P46650|https://www.uniprot.org/uniprot/P41693|https://www.uniprot.org/uniprot/P41683|https://www.uniprot.org/uniprot/P41323|https://www.uniprot.org/uniprot/P29455|https://www.uniprot.org/uniprot/P26893|https://www.uniprot.org/uniprot/P26892|https://www.uniprot.org/uniprot/P20607|https://www.uniprot.org/uniprot/P08505|https://www.uniprot.org/uniprot/P05231|https://www.uniprot.org/uniprot/O46568|https://www.uniprot.org/uniprot/O35736|https://www.uniprot.org/uniprot/O19007|https://www.uniprot.org/uniprot/B6CKP4|https://www.uniprot.org/uniprot/A9QWQ9|https://www.uniprot.org/uniprot/A3FBE9|https://www.uniprot.org/uniprot/A0S0B0

LitCovid-sample-Enju

Id Subject Object Predicate Lexical cue
T222 1-12 NNP denotes Tocilizumab
T223 12-13 -COMMA- denotes ,
T224 14-15 DT denotes a
T225 16-26 JJ denotes monoclonal
T226 27-35 NN denotes antibody
T227 36-43 IN denotes against
T228 44-47 NN denotes IL6
T229 47-48 -COMMA- denotes ,
T230 49-54 MD denotes could
T231 55-61 VB denotes confer
T232 62-70 JJ denotes clinical
T233 71-78 NN denotes benefit
T234 79-81 IN denotes in
T235 82-90 NNS denotes patients
T236 91-95 IN denotes with
T237 96-100 JJ denotes high
T238 101-104 NN denotes IL6
T239 105-111 NNS denotes levels
T240 113-122 JJ denotes Essential
T241 123-131 NNS denotes elements
T242 132-136 IN denotes that
T243 137-144 NN denotes process
T244 145-154 NN denotes SARS-CoV2
R213 T222 T223 arg1Of Tocilizumab,","
R214 T226 T223 arg2Of antibody,","
R215 T226 T224 arg1Of antibody,a
R216 T226 T225 arg1Of antibody,monoclonal
R217 T226 T227 arg1Of antibody,against
R218 T228 T227 arg2Of IL6,against
R219 T231 T229 arg1Of confer,","
R220 T222 T230 arg1Of Tocilizumab,could
R221 T231 T230 arg2Of confer,could
R222 T222 T231 arg1Of Tocilizumab,confer
R223 T233 T231 arg2Of benefit,confer
R224 T233 T232 arg1Of benefit,clinical
R225 T231 T234 arg1Of confer,in
R226 T235 T234 arg2Of patients,in
R227 T235 T236 arg1Of patients,with
R228 T239 T236 arg2Of levels,with
R229 T239 T237 arg1Of levels,high
R230 T239 T238 arg1Of levels,IL6
R231 T241 T240 arg1Of elements,Essential
R232 T241 T242 arg1Of elements,that

LitCovid-sample-PD-FMA

Id Subject Object Predicate Lexical cue fma_id
T5 27-35 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871

LitCovid-sample-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T18 145-154 Disease denotes SARS-CoV2 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T19 1-112 Sentence denotes Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels.